Evogene (TSE:EVGN – Free Report) had its price objective reduced by Desjardins from C$4.00 to C$3.00 in a research note published on Tuesday,BayStreet.CA reports. They currently have a buy rating on the stock.
Separately, Ventum Financial reduced their price objective on shares of Evogene from C$4.00 to C$3.00 in a research note on Friday, November 22nd.
Get Our Latest Stock Report on Evogene
Evogene Price Performance
Evogene Company Profile
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Recommended Stories
- Five stocks we like better than Evogene
- What is a Special Dividend?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Tesla Stock: Finding a Bottom May Take Time
- Insider Trading – What You Need to Know
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
